[Cost-effectiveness Analysis of Blue Light Cystoscopy with Hexylaminolevulinate in Transurethral Resection of the Bladder]

Overview

Journal Urologe A

Specialty Urology

Date 2018 Apr 12

PMID 29637215

Citations 4

Authors

G Gakis

B Volkmer

B Qvick

F Marteau

A Stenzl

Affiliations

Soon will be listed here.

Abstract

Background: Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transurethral resection of bladder tumours (TURB) improves the detection rate of bladder cancer and leads to fewer recurrences.

Objectives: A cost-effectiveness analysis was carried out in order to calculate the consequences for the German healthcare system.

Methods: We combined a short-term decision tree and a Markov model to evaluate outcomes over a long period of time. The alternatives investigated were HAL-assisted blue light cystoscopy (BLC) as adjunct to WLC (HAL + BLC/WLC) compared with WLC alone in patients undergoing TURB.

Results: HAL + BLC/WLC compared to WLC alone was associated with 0.07 incremental quality-adjusted life years (QALYs) and cost savings of 537 € per patient.

Conclusion: HAL + BLC/WLC compared with WLC alone resulted in both cost savings and improved patient outcome rendering it the "dominant" strategy.

Citing Articles

Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2021; 21(12):1-123.

PMID: 34484486 PMC: 8382283.

Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network....

Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Katayama S, Grossmann N BJU Int. 2021; 128(3):280-289.

PMID: 33683778 PMC: 8453975. DOI: 10.1111/bju.15383.

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.

Todenhofer T, Maas M, Ketz M, Kossack N, Colling C, Qvick B World J Urol. 2021; 39(8):2953-2960.

PMID: 33569642 PMC: 8405483. DOI: 10.1007/s00345-020-03587-0.

Enhanced Endoscopy in Bladder Cancer.

Pearce S, Daneshmand S Curr Urol Rep. 2018; 19(10):84.

PMID: 30116985 DOI: 10.1007/s11934-018-0833-9.

References

Millan-Rodriguez F, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J . Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000; 164(3 Pt 1):680-4. DOI: 10.1016/s0022-5347(05)67280-1. View

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm M . Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005; 174(3):862-6. DOI: 10.1097/01.ju.0000169257.19841.2a. View

Brauer C, Neumann P . Quality-adjusted life years: how useful in medico economic studies. Fundam Clin Pharmacol. 2005; 19(6):603-7. DOI: 10.1111/j.1472-8206.2005.00369.x. View

Burger M, Zaak D, Stief C, Filbeck T, Wieland W, Roessler W . Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol. 2007; 52(1):142-7. DOI: 10.1016/j.eururo.2007.01.064. View

Fradet Y, Grossman H, Gomella L, Lerner S, Cookson M, Albala D . A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007; 178(1):68-73. DOI: 10.1016/j.juro.2007.03.028. View

Kulkarni G, Finelli A, Fleshner N, Jewett M, Lopushinsky S, Alibhai S . Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 2007; 4(9):e284. PMC: 1989749. DOI: 10.1371/journal.pmed.0040284. View

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T . Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010; 14(4):1-331, iii-iv. DOI: 10.3310/hta14040. View

10.

Witjes J, Palou Redorta J, Jacqmin D, Sofras F, Malmstrom P, Riedl C . Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol. 2010; 57(4):607-14. DOI: 10.1016/j.eururo.2010.01.025. View

11.

Stenzl A, Burger M, Fradet Y, Mynderse L, Soloway M, Witjes J . Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010; 184(5):1907-13. PMC: 4327891. DOI: 10.1016/j.juro.2010.06.148. View

12.

Hermann G, Mogensen K, Carlsson S, Marcussen N, Duun S . Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011; 108(8 Pt 2):E297-303. DOI: 10.1111/j.1464-410X.2011.10090.x. View

13.

Rink M, Chun F, Chromecki T, Fajkovic H, Dahlem R, Fisch M . [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies]. Urologe A. 2012; 51(6):820-8. DOI: 10.1007/s00120-011-2769-2. View

14.

Grossman H, Stenzl A, Fradet Y, Mynderse L, Kriegmair M, Witjes J . Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012; 188(1):58-62. PMC: 3372634. DOI: 10.1016/j.juro.2012.03.007. View

15.

Sommerauer M, Jocham D, Laturnus J . [Non-muscle invasive transitional cell carcinoma of the bladder. New developments in diagnostics and therapy]. Urologe A. 2012; 51(6):791-7. DOI: 10.1007/s00120-012-2897-3. View

16.

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

17.

Witjes J, Palou J, Soloway M, Lamm D, Kamat A, Brausi M . Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013; 112(6):742-50. PMC: 3933735. DOI: 10.1111/bju.12012. View

18.

Garfield S, Gavaghan M, Armstrong S, Stephen Jones J . The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013; 20(2):6682-9. View

19.

Burger M, Grossman H, Droller M, Schmidbauer J, Hermann G, Dragoescu O . Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5):846-54. DOI: 10.1016/j.eururo.2013.03.059. View

20.

Witjes J . Is fluorescent cystoscopy of cost/benefit/therapeutic value for carcinoma in situ of the bladder? Yes. J Urol. 2013; 190(1):19-20. DOI: 10.1016/j.juro.2013.04.038. View